Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

doi:10.1038/s41591-024-03462-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

Nature medicine - 1 Mar 2025

Okines Alicia F C, Curigliano Giuseppe, Mizuno Nobumasa, Oh Do-Youn, Rorive Andree, Soliman Hatem, Takahashi Shunji, Bekaii-Saab Tanios, Burkard Mark E, Chung Ki Y, Debruyne Philip R, Fox Jenny R, Gambardella Valentina, Gil-Martin Marta, Hamilton Erika P, Monk Bradley J, Nakamura Yoshiaki, Nguyen Danny, O'Malley David M, Olawaiye Alexander B, Pothuri Bhavana, Reck Martin, Sudo Kazuki, Sunakawa Yu, Van Marcke Cedric, Yu Evan Y, Ramos Jorge, Tan Sherry, Bieda Mark, Stinchcombe Thomas E, Pohlmann Paula R

Abstract excerpt

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Neoplasm Metastasis

Share to Oxazoles

Share to Pyridines

Share to Quinazolines

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 39825152
DOI: 10.1038/s41591-024-03462-0
PMCID: PMC11922774

Genes

ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.PMID 39825152Read ↗

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.Semantic proximity Read ↗

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.Semantic proximity Read ↗

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.Semantic proximity Read ↗

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.Semantic proximity Read ↗

Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsSemantic proximity Read ↗

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerSemantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Semantic proximity Read ↗

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.Semantic proximity Read ↗

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.Semantic proximity Read ↗

HER2 aberrations in cancer: implications for therapy.Semantic proximity Read ↗

Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.